Inloggen

Login
 
Wachtwoord vergeten?

Aandeel Novacyt PSE:ALNOV, FR0010397232

  • 12,140 19 jan 2021 17:38
  • -0,060 (-0,49%) Dagrange 11,520 - 12,220
  • 1.527.924 Gem. (3M) 2,9M

Waar beleggen jullie nog meer in

2.095 Posts
Pagina: «« 1 ... 65 66 67 68 69 ... 105 »» | Laatste | Omlaag ↓
  1. Whoopie 17 juli 2020 20:11
    quote:

    Hansvdz schreef op 17 juli 2020 10:23:


    Hou ook BNGO in de gaten, ik geloof in dit bedrijf (heb er heel wat aandelen van) en hebben gisteren nieuws geplaatst op het einde van de dag: ir.bionanogenomics.com/news-releases/...


    Had ze ook al een tijdje, maar vandaag toch aan 0,68 buitengegooid.
    Lichte winst van 15% gepakt.

    Achteraf gezien had ik beter kunnen timen, maar zo is er altijd wel iets.
  2. KC 1965 17 juli 2020 20:28
    Nabriva Therapeutics plc (NBRV)
    NasdaqGS - NasdaqGS Real Time Price. Currency in USD
    Add to watchlist

    Quote Lookup

    0.9107+0.0707 (+8.4167%)
    As of 2:24PM EDT. Market open.

    Ondanks de releases blijft de stijging beperkt.

    Analyst Sees 60% Upside for Nabriva (NBRV) Following Merck Deal
    TipRanks•July 17, 2020
    As a general rule, when you hear about a tiny biotech "partnering" with a Big Pharma giant to market a drug, it's the smaller company that's doing all the work -- and the larger company that's providing the marketing heft (and the money to market the drug). But this news is a bit different. In fact, it's the exact opposite of what you'd ordinarily expect.

    Nabriva Therapeutics (NBRV), a microcap biotech based in Dublin, Ireland, announced Thursday that it will partner up with American Big Pharma giant Merck (MRK) to market Merck's "SIVEXTRO" antibiotic for treating acute bacterial skin and skin structure infections (ABSSSI) caused by Gram-positive pathogens (bacteria that produce a crystal violet stain result when subjected to the Gram stain test).

    SIVEXTRO is used to treat such common conditions as abscesses, cellulitis, and wound infections often caused by Staphylococcus aureus and Streptococcus pyogenes.

    Merck owns the rights to SIVEXTRO, originally approved by the US Food and Drug Administration in 2014. Nabriva will be buying SIVEXTRO produced by Merck "at specified prices" -- with no upfront payment due to Merck -- then turning around and marketing, selling, and distributing the drug to its U.S. customers with "commercial and sales services" assistance from privately-held Amplity Health. The agreement gives Nabriva these rights initially through the end of 2023 (sales are expected to begin on January 1, 2021). Absent cancellation by either party, the agreement will automatically renew for three-year-long extensions following that initial period.

    Northland analyst Carl Byrnes explained the significance of this development for Nabriva in a "flash note" issued shortly after the announcement.

    In essence then, the significance of this deal is this: Nabriva is obtaining the right to buy and resell a commonly used antibiotic, incurring no costs to develop it, no upfront cost to acquire its rights, and Nabriva can enjoy whatever profit margin it is able to build into the difference between the prices it pays Merck to buy the drug, and the prices it can convince its customers to pay. Nabriva doesn't even incur much in the way of fixed costs, as its agreement with Amplity will be both "flexible and scalable." (Merck, for its part, gets a bigger market for the drug without making any independent efforts of its own).

    Byrnes believes that Nabriva is getting the better part of this deal, as it could, in combination with the company's other drugs, significantly boost Nabriva's currently tiny revenue stream of only $8.6 million in annual sales. Indeed, in the analyst's estimation, the first year of this agreement being in effect could see Nabriva's sales jump 16%, to $10 million -- and sales could more than double the next year, to $25 million.

    Accordingly, Byrnes is reiterating his Outperform (i.e. Buy) rating on Nabriva stock, with a $1.50 price target that implies nearly 60% upside from the stock's current $0.91 share price. (To watch Byrnes' track record, click here)

    Not all analysts on the street voice Byrnes' bullish forecast for Nabriva. Overall, based on 3 analysts polled by TipRanks in the last 3 months, 2 other analysts recommend investors to stay sidelined. (See NBRV stock analysis on TipRanks)

    Deze gaat toch echt binnenkort knallen denk ik.
  3. KC 1965 19 juli 2020 11:48
    Ik heb een goed gevoel bij NBRV/Nabriva, ze hebben afgelopen week enkel goed nieuws gebracht en de vooruitzichten zijn goed.

    Huidige koers:
    Nabriva Therapeutics AG (NBRV)

    NASDAQ
    Melding aanmaken
    Voeg toe aan Portfolio
    0,912 +0,072 +8,55%
    17/07 - Gesloten. Valuta in USD ( Algemene voorwaarden )
    Nabeurs 0,920 +0,008 +0,888% 1:59:57 - Real-time Data
    Type: Aandeel
    Markt: Verenigde Staten
    ISIN: IE00BYQMW233
    CUSIP: 00BYQMW23
    Volume: 27.235.077 Bied/laat: 0,910 / 0,920 Dagbereik: 0,900 - 0,988
    Nabriva Therapeutics 0,912 +0,072 +8,55%

    Ik heb er vrijdag nog een pluk toegevoegd aan 0,91.

    Hou die in het oog.
  4. Gaizka1985 19 juli 2020 12:57
    quote:

    KC 1965 schreef op 19 juli 2020 11:48:


    Ik heb een goed gevoel bij NBRV/Nabriva, ze hebben afgelopen week enkel goed nieuws gebracht en de vooruitzichten zijn goed.

    Huidige koers:
    Nabriva Therapeutics AG (NBRV)

    NASDAQ
    Melding aanmaken
    Voeg toe aan Portfolio
    0,912 +0,072 +8,55%
    17/07 - Gesloten. Valuta in USD ( Algemene voorwaarden )
    Nabeurs 0,920 +0,008 +0,888% 1:59:57 - Real-time Data
    Type: Aandeel
    Markt: Verenigde Staten
    ISIN: IE00BYQMW233
    CUSIP: 00BYQMW23
    Volume: 27.235.077 Bied/laat: 0,910 / 0,920 Dagbereik: 0,900 - 0,988
    Nabriva Therapeutics 0,912 +0,072 +8,55%

    Ik heb er vrijdag nog een pluk toegevoegd aan 0,91.

    Hou die in het oog.



    Ik heb er ook een aantal. vooruitzichten lijken goed inderdaad!
  5. KC 1965 20 juli 2020 07:54
    Dit gaat toch ook zeer goed de afgelopen week en nu de TO:

    EUROPLASMA
    EURONEXT GROWTH PARIS
    FR0013514114 - STOCK


    CAC 40 -0.31% SBF 120 -0.39% EUR / USD 0.17% GROWTH ALL -0.16%

    € 5.05
    PREOPEN
    17/07/2020 - 17:38 CET
    Since Open
    +1.95 (+62.90%)
    Since Previous Close
    +2.30 (+83.64%)
    image
    Theoretical Opening Price 7.00
2.095 Posts
Pagina: «« 1 ... 65 66 67 68 69 ... 105 »» | Laatste |Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

Novacyt Meer »

Koers 12,140   Verschil -0,06 (-0,49%)
Laag 11,520   Volume 1.527.924
Hoog 12,220   Gem. Volume 2.904.203
19 jan 2021 17:38
label premium

KOPEN OF VERKOPEN?

Het laatste advies leest u als IEX Premium-lid

Ontdek Premium
 
Quotedata: Amsterdam realtime by Euronext, other realtime by Cboe Europe Ltd.   US stocks: by NYSE & Cboe BZX Exchange, 15min delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by Infront. Crypto data by Crypto Compare